Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J. Castellano D, et al. Among authors: anton aparicio l. Expert Opin Drug Saf. 2018 Jun;17(6):573-579. doi: 10.1080/14740338.2017.1330410. Epub 2017 Aug 28. Expert Opin Drug Saf. 2018. PMID: 28535693 Free article.
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Castellano D, Antón Aparicio LM, Esteban E, Sánchez-Hernández A, Germà JR, Batista N, Maroto P, Pérez-Valderrama B, Luque R, Méndez-Vidal MJ; cabazitaxel EAP study. Castellano D, et al. Among authors: anton aparicio lm. Expert Opin Drug Saf. 2014 Sep;13(9):1165-73. doi: 10.1517/14740338.2014.939583. Epub 2014 Jul 7. Expert Opin Drug Saf. 2014. PMID: 25001524 Clinical Trial.
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
Gámez-Pozo A, Antón-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, de Portugal T, Ramos-Vázquez M, Pérez-Carrión R, Bolós MV, Madero R, Sánchez-Navarro I, Fresno Vara JA, Espinosa Arranz E. Gámez-Pozo A, et al. Neoplasia. 2012 Dec;14(12):1144-52. doi: 10.1593/neo.12734. Neoplasia. 2012. PMID: 23308047 Free PMC article.
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P. Capdevila J, et al. Among authors: anton aparicio l. BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6. BMC Cancer. 2015. PMID: 26138480 Free PMC article.
New insights into molecular mechanisms of sunitinib-associated side effects.
Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Antón-Aparicio L. Aparicio-Gallego G, et al. Mol Cancer Ther. 2011 Dec;10(12):2215-23. doi: 10.1158/1535-7163.MCT-10-1124. Mol Cancer Ther. 2011. PMID: 22161785 Review.
56 results